Protext Mobility Inc
OTC:TXTM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Protext Mobility Inc
EPS (Diluted)
Protext Mobility Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Protext Mobility Inc
OTC:TXTM
|
EPS (Diluted)
-$2
|
CAGR 3-Years
71%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$6
|
CAGR 3-Years
23%
|
CAGR 5-Years
132%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$14
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$41
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
22%
|
|
Protext Mobility Inc
Glance View
ProText Mobility, Inc. engages in the development of pharmaceutical applications for botanical drugs. The company is headquartered in Delray Beach, Florida. The company went IPO on 2003-08-21. The firm is engaged in the research, clinical testing and commercialization of bioavailable botanical products, which includes all-natural ingredients formulated for nutraceutical and pharmaceutical applications. The firm is focused on the development of pharmaceutical applications for botanical drugs and has the license to develop Phytofare in botanical drug applications. The Phytofare is bioavailable extract produced from live green tea leaves that has been clinically proven in double-blind human trials to have greater bioavailability over generic extract. The Company’s subsidiaries include EchoMetrix, Plandai Biotechnology and Cannabis Biosciences, Inc.
See Also
What is Protext Mobility Inc's EPS (Diluted)?
EPS (Diluted)
-2.3
USD
Based on the financial report for Dec 31, 2013, Protext Mobility Inc's EPS (Diluted) amounts to -2.3 USD.
What is Protext Mobility Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
49%
Over the last year, the EPS (Diluted) growth was 75%. The average annual EPS (Diluted) growth rates for Protext Mobility Inc have been 71% over the past three years , 49% over the past five years .
